

RESEARCH

Open Access

Sequence and gene expression of chloroquine resistance transporter (*pfCRT*) in the association of *in vitro* drugs resistance of *Plasmodium falciparum*

Wanna Chaijaroenkul^{1†}, Stephen A Ward^{2†}, Mathirut Mungthin^{3†}, David Johnson^{2†}, Andrew Owen^{4†}, Patrick G Bray², Kesara Na-Bangchang^{1*}

Abstract

Background: *Plasmodium falciparum* chloroquine resistance (CQR) transporter protein (PfCRT) is known to be the important key of CQR. Recent studies have definitively demonstrated a link between mutations in the gene *pfCRT* and resistance to chloroquine in *P. falciparum*. Although these mutations are predictive of chloroquine resistance, they are not quantitatively predictive of the degree of resistance.

Methods: In this study, a total of 95 recently adapted *P. falciparum* isolates from Thailand were included in the analysis. Parasites were characterized for their drug susceptibility phenotypes and genotypes with respect to *pfCRT*. From the original 95 isolates, 20 were selected for complete *pfCRT* sequence analysis.

Results: Almost all of the parasites characterized carried the previously reported mutations K76T, A220S, Q271E, N326S, I356T and R371I. On complete sequencing, isolates were identified with novel mutations at K76A and E198K. There was a suggestion that parasites carrying E198K were less resistant than those that did not. In addition, *pfCRT* and *pfmdr1* gene expression were investigated by real-time PCR. No relationship between the expression level of either of these genes and response to drug was observed.

Conclusion: Data from the present study suggest that other genes must contribute to the degree of resistance once the resistance phenotype is established through mutations in *pfCRT*.

Background

Malaria, especially that caused by *Plasmodium falciparum*, is a serious health problem in many tropical countries and this situation is made worse as a consequence of drug resistance. The 4-aminoquinoline chloroquine (CQ) was introduced in the 1940's as a cheap and effective treatment for malaria. Chloroquine-resistant (CQR) parasites were first reported in the late 1950s from South-East Asia and South-America. Since those early reports, CQR *P. falciparum* has spread throughout the malaria endemic world. In addition, in some areas such as the Thai-Myanmar and the Thai-Cambodian borders, parasite populations resistant to most available drugs have evolved. These parasites

have been referred to as multidrug-resistant (MDR) *P. falciparum* [1].

Reduced drug accumulation is a phenotypic feature of CQR which can be partially reversed by the calcium channel blocker verapamil, an agent that also reverses chloroquine resistance [2-5]. Two genes have been linked with this phenotype namely *pfmdr1* and *pfCRT*. The *pfmdr1* gene is located on chromosome 5 and *pfCRT* gene is located on chromosome 7. The weight of molecular evidence suggests that while *pfmdr1* may have a modulatory effect in parasite susceptibility to CQ [6], mutation in *pfCRT* is the principal determinant of CQR [7].

Several mutations have been identified in the *pfCRT* gene. CQR *P. falciparum* strains from South East Asia and Africa carry point mutations at codons 74, 75, 76, 220, 271, 326 and 371, whereas, CQR South American parasites carry point mutations at codons 76, 220 and either 72, 326 and 356 or 75, 97 and 371 [8]. The (K76T) mutation is

* Correspondence: kesaratmu@yahoo.com

† Contributed equally

¹Faculty of Allied Health Sciences, Thammasat University, Rangsit, Patumthani 12120, Thailand

Full list of author information is available at the end of the article

strongly associated with CQ susceptibility and clinical outcomes. Transfection studies have confirmed the importance of this amino acid change [9]. The PfCRT protein is localized to the digestive vacuole membrane and appears to be an integral membrane protein with an as yet unidentified transport function. Hypotheses have been proposed to explain CQR that implicate PfCRT function as either an ion channel or as a direct drug transporter. In addition to mutation in *pfprt* being involved in CQR, it has also been suggested that the level of *pfprt* expression has an impact on parasite susceptibility [10]. Waller *et al* demonstrated that lines transfected with *pfprt* alleles associated with CQR displayed a 30-40% reduction in protein expression together with an increase in CQ sensitivity [10]. In contrast, Durrand *et al* failed to identify any correlation between the CQ response of field isolates and *pfprt* gene expression [11].

It is generally accepted that PfCRT is the principal determinant of CQR. However, it is not possible to predict the degree of CQR based on the *pfprt* genotype alone or even in combination with *pfmdr1* genotype. It is clear from our own surveillance studies and those of others that parasites considered to be CQR in actual fact display a broad range of sensitivity to the drug. In this study, the phenotype-genotype relationship between 95 recently adapted isolates of *P. falciparum* from Thailand were characterized. Furthermore, 20 selected isolates were fully sequenced for *pfprt* gene in order to look for novel mutations that might be implicated in the degree of CQR.

Methods

Parasite isolates

Clinical *P. falciparum* isolates were collected from malaria endemic areas of Thailand including the Thai-Myanmar (Kanchanaburi, Tak, Ratchaburi and Ranong Provinces) and Thai-Combodian borders (Chantaburi Province) between 1998 and 2003 prior to the initiation of antimalarial treatment. Blood samples from individual patients were collected under a clinical protocol approved by the Ethics Committee of the Ministry of Public Health of Thailand. Briefly, three to five millilitres of blood were collected into EDTA tubes from patients with a confirmed diagnosis of uncomplicated *P. falciparum* malaria. The fresh blood samples were then centrifuged to remove the buffy coat and cryopreserved in liquid nitrogen following the method of Rowe *et al* [12] before being transported to Pharmacology and Toxicology Unit, Graduate Programme in Biomedical Sciences, Thammasat University.

Parasite culture and drug susceptibility assay

Parasites were maintained in *in vitro* culture using the method of Trager and Jensen [13]. *In vitro* susceptibility

to chloroquine and a series of related compounds, in the presence or absence of verapamil was tested by monitoring [³H]Hypoxanthine uptake [14]. Briefly, each drug was prepared as 10 mM in 50% ethanol for stock solution, and further diluted with RPMI-1640 complete media in desired concentrations. Each well in 96-well plate contained 100 μ l of drug solution and 10 μ l of 1% parasitaemia and 20% haematocrit. The plates were incubated at 37°C in gas chamber (95% N₂, 5% O₂, 5% CO₂) for 24 hours, then pulsed with 5 μ l of [³H] hypoxanthine solution (0.1 mCi/ml), and reincubated for an additional 24 hours. The plates were harvested and measured with a 1450 MicroBeta Trilux liquid scintillation and luminescence counter (Wallac Co. Ltd., Finland). The drug concentration that inhibited 50% parasite growth (IC₅₀) were determined.

PCR amplification of *P. falciparum* genes

Genomic DNA was extracted using Chelex-resin (Biorad, USA) according to the method of Wooden *et al* [15]. Genetic variation between parasites was investigated by a multiplex PCR fingerprint technique [15]. Previously published nested and allele-restricted PCR methods were employed to detect *pfmdr1* N86Y [16] and *pfprt* mutations [7] respectively. For all assays, the laboratory adapted Thai K1 parasite isolate was used as a positive control for the mutant genotype and the Gambia isolate, G112 (a gift from the Malaria Research Unit, Chulalongkorn University, Thailand) as a positive control for the wild type genotype.

DNA sequencing analysis

The *pfprt* gene was amplified from genomic DNA using a nested PCR strategy. Exons 1-2, 3-8 and 9-13 were sequenced independently using the primers shown in Table 1. Each reaction contained 1.5 mM MgCl₂, 200 mM dNTPs, 1 mM each primer, 1 \times PCR buffer and 2 U of *Taq* polymerase (Promega, USA) in a total volume of 50 μ l. The thermal cycle conditions were 94°C for 3 min, and 35 cycles of 92°C for 30 sec, 55°C for 30 sec, 62°C for 1 min 30 sec and a final extension at 62°C for 5 min. The second round of amplification for exon 1-2 was 94°C for 4 min, 35 cycles of 92°C for 1 min, 60°C for 1 min, 72°C for 1 min and a final extension step of 72°C for 5 min. PCR products were purified using Wizard SV gel and PCR clean up system (Promega, USA) according to the manufacturers instructions. Each amplicon was then cloned with the TOPO TA Cloning kit (Invitrogen Life Technologies) and the positive clones were picked from white or blue colonies following overnight incubation in selection media, S-Gal (Sigma, USA). The plasmid DNA was purified using a MiniPrep Kit (Promega, USA) and digested with the restriction enzyme *EcoRI* to confirm the correct

Table 1 Primers used for *pfprt* sequencing and real-time PCR quantification

Exon 1-2	
Primary	
E1/2-F	CGACATTCGATATATTATTTTTAGAC
E1/2-R	TATATGTGTAATGTTTTATATTGG
Nested	
E1/2-NF	CCGTAATAATAAATACACGCAG
E1/2-NR	AATGTTTTATATTGGTAGGTGG
Exon 3-8	
Primary	
E3/8-F	CCACCTACCAATATAAAACATTAC
E3/8-R	GTTAAAATATATATAAATGTCTC
Nested	
E3/8-NF	TATATATATATGTATGTATGTTG
E3/8-NR	AATGTCTCTTATAATTTGAAATT
Exon 9-13	
Primary	
E9/13-F	CTTATAATAAAATTTCAAATATAAGAGAC
E9/13-R	GAGATCTCTATACCTTCAACATTATTC
Nested	
E9/13-NF	GAGACATTTATATATTTTTAAC
E9/13-NR	CCTTATAAAGTGAATGCG
<i>pfprt</i> RT-PCR	
<i>pfprt</i> -F	CTTTATTTGTATGATTATGTTCTTTATTGTTTATTCCTTATTTGGA
<i>pfprt</i> -R	AACAGGCATCTAACATGGATATAGCAAA
<i>pfprt</i> -probe	TCCGGTGTCTGTTCTTTG
<i>pfmdr</i> RT-PCR	
<i>pfmdr</i> -F	GCATTCGGTTTTGGTATGGTACAA
<i>pfmdr</i> -R	CCTAATAAAATGGATATACTGAGGCACCA
<i>pfmdr</i> -probe	ACGAATCAATACCCCAATAAT
EF-1a RT-PCR	
EF-1a-F	GGCAGAAAGAGAAAGAGGTATTACCA
EF-1a-R	CCTGGTGCATCAATGACAGTAAAGA
EF-1a-probe	TTATGGAAATTTGAAACCCC

insertion. Finally, sequencing was carried out using the M13 forward and reverse primers and DNASTar (Laser-gene) was utilized for sequence analysis.

***Pfprt* and *pfmdr1* real-time reverse transcription PCR quantification**

Pfprt and *pfmdr1* gene expression were determined by real-time reverse transcription PCR. Since *pfprt* and *pfmdr1* have previously been reported to be preferentially expressed during the trophozoite state, analysis was restricted to isolates at the trophozoite stage. Total RNA was extracted by standard methodology using Trizol™ (Invitrogen, USA) [17]. For *pfprt*, EF-1a primers were designed to cross introns. However, this was not

possible for *pfmdr1* since it is a one-exon gene. Therefore, each sample was treated with DNase prior to reverse transcription (Invitrogen, USA) in order to negate the possibility of amplifying genomic DNA. The sequences of forward and reverse primers as well as the sequences of the specific reporter probes (FAM-labelled in all cases) are shown in Table 1. Quantification was achieved by standard *taqMan* methodology as previously reported [18].

Detection of gene copy number of *pfmdr1* by SYBR Green I real-time PCR

Pfmdr1 copy number was determined by SYBR Green I real-time PCR (iCycler, Bio-Rad, USA) using the default thermocycler program for all genes: 10 minutes of pre-incubation at 95°C followed by 40 cycles for 15 seconds at 95°C and one minute at 60°C. The oligonucleotide primers were designed by Ferreira [19] with modification. Individual real-time PCR reaction was carried out in 25 µl volume in a 96-well plate containing 1× buffer (10×), 3.5 mM MgCl₂, 200 µM dNTPs, 1 mM each of sense and antisense primers, 12.5 ml of Platinum™ PCR SuperMix (Invitrogen, USA). The 2^{-ΔΔC_t} method of relative quantification was adapted to estimate copy numbers in *P. falciparum* genes. In this work, genomic DNA extracted from *P. falciparum* 3D7, known to harbour a single copy of each gene studied, was used as a calibrator, while Pf-β-actin 1 was served as the house-keeping gene in all experiments. Dd2 genomic DNA was used as a second calibrator containing four copies of *pfmdr1*. A minimum of two experiments was carried out for each gene and each sample. In each experiment, each individual sample was run in duplicate wells and the C_t of each well was recorded at the end of the reaction.

Statistical analysis

All data are expressed as mean ± standard deviation. Data were assessed for normality using a Shapiro-Wilk statistical test. A Kruskal-Wallis statistical test was utilized to assess the relationship between mutations in *pfprt* and *pfmdr1* and drug IC₅₀. Correlations were assessed by Spearman Rank test. Statistical significance for all tests was set at a α = 0.05.

Results

Genetic polymorphisms of *P. falciparum* isolates

A total of 95 isolates (excluding the laboratory lines: K1, G112, M12 and T9/94b3) were successfully cultured and analysed. Of these, 13 were obtained from the Tak Province of Thailand, 37 from Kanchanaburi, 16 from Ranong, 1 from Ratchaburi, and 14 were from Chantaburim Provinces. Fourteen isolates were of unknown origin. Tak, Kanchanaburi and Ranong are provinces that lie along the Thai-Myanmar border; the first two areas have been described as 'high mefloquine-resistance

areas', whereas the third is described as a 'low mefloquine-resistance area'. Chantaburi Province is located along the Thai-Cambodian border and is defined as a 'high mefloquine-resistance area' (Ministry of Public Health, Thailand [20].

Based on the results of the PCR fingerprints, all but two infections were clonal containing only one parasite population with a single genotype of either *msp1*, *msp2* or *csp*. Two isolates showed PCR fingerprint suggesting a mixed-infection. Genotyping for *pfcr1* revealed a 100% prevalence of the 76T, 220S, 271E, 326S and 371I mutations (95 of 95 samples) with a 94% prevalence of the 356T Mutation (89 of 95 samples). The K1-type mutation of the *pfmdr1* was seen in only 5% (5 of 95) of the samples with almost all isolates containing the wild type Asn at position 86.

In vitro drug sensitivity test

A total of 90 isolates were tested for sensitivity to chloroquine (CQ), quinine (QN), mefloquine (MQ), and dihydroartemisinin (DHA). The sensitivity of the isolates to CQ and QN was also assessed in the presence or absence of the resistance reverser verapamil (VP: 5 mM). Sensitivity of the isolates to CQ, QN and MQ was categorized based on IC_{50} values described by Cerutti *et al*, [21].

CQ sensitivity was categorized into either highly resistant (HR: $IC_{50} >101$ nM), moderately resistant (MR: $30.9 < IC_{50} \leq 100.9$ nM) or sensitive (S: $IC_{50} \leq 30.9$ nM) (Figure 1A). Based on these criteria, 30 (32%), 61 (64%), and 4 (4%) isolates were categorized as HR, MR, and S, respectively. The corresponding values for geometric mean (95% CI) IC_{50} were 130.9 (122.1-140.2), 60.8

(56.7-65.3), and 23.0 (20.5-25.5) nM, respectively. All resistant isolates demonstrated a verapamil reversible component of resistance.

QN sensitivity was categorized as either resistant (R: $IC_{50} >500$ nM) or sensitive (S: $IC_{50} \leq 500$ nM). Based on these criteria, 1 (1%), and 92 (99%) isolates were categorized as R, and S, respectively. The corresponding values for geometric mean (95% CI) IC_{50} were 654.4 and 144.4 (129.4-161) nM, respectively. All isolates were chemosensitized verapamil.

MQ sensitivity was categorized as either resistant (R: $IC_{50} >24$ nM) or sensitive (S: $IC_{50} \leq 24$ nM) (Figure 1B). Based on these criteria, 44 (32%), and 47 (68%) isolates were categorized as R, and S, respectively. The corresponding values for geometric mean (95% CI) IC_{50} were 38.2 (34.4-42.4), and 13.3 (11-16) nM, respectively.

The IC_{50} of DHA for different isolates ranged from 0.37 to 4.87 nM, with the geometric mean (95% CI) of 1.42 (1.24-1.64) nM.

The relationship between genotype and phenotype

Based on the known mutations in *pfcr1* and *pfmdr1*, there was no statistically significant association between susceptibility of *P. falciparum* isolates to CQ, QN and MQ and *pfcr1* polymorphisms, as well as between susceptibility to CQ and QN and *pfmdr1* polymorphisms. However, there was a tendency (no statistical significance) of reduced MQ susceptibility in *pfmdr1* mutant isolates.

Novel sequence polymorphisms in *pfcr1*

A total of 20 isolates selected from either the moderately or highly CQ resistant subgroups were fully




Figure 1 Box plot between $log_{10} IC_{50}$ and the order of drug susceptibility. A: CQ was categorised into high resistance (HR: $IC_{50} >101$ nM), moderate resistance (MR: $30.9 < IC_{50} \leq 100.9$ nM) and sensitive (S; $IC_{50} \leq 30.9$ nM). B: MQ was divided into 2 groups; resistant (R; $IC_{50} >24$ nM and sensitive (S; $IC_{50} \leq 24$ nM).

sequenced for the *pfcr* gene in order to establish if other, as yet unknown mutations could discriminate between these two levels of *in vitro* susceptibility. The derived sequences were compared with the sequences of the 3D7 and Dd2 parasites from the PlasmoDB database. The sequencing results are summarized in Table 2. There were several new mutations identified at a number of novel positions, which conferred an amino acid alteration compared to 3D7. However, it was not possible in this study to directly link these sequence differences with CQ susceptibility. Although most of the parasites had the familiar "CVIET" sequence at positions 72-76, the J9 isolate from Chantaburi contained the novel mutation at codon 76 with a different amino acid substitution K76A. This is a unique position 76 mutation, which has never been reported before in field isolates. In addition, this field isolate carried other mutations at positions S39P and N277D.

Four of the field isolates categorized as displaying moderate CQ resistance carried a E198K mutation which may be functionally relevant. Furthermore, deletions in the *pfcr* sequence were observed at position 327 in isolate BC7 and 251 in isolate KS28. These two

deletions occurred at exon 2. Interestingly, the A144T or A144F mutation newly described in isolates from the Philippines and Cambodia was not detected in these Thai isolates [8,22].

Pfcr and *pfmdr1* gene expression

The correlation between *pfcr* and *pfmdr1* gene expression (determined by RT-PCR) and *in vitro* response is shown in Figures 2 and 3. In this study, there was no statistically significant correlation between expression levels of either gene and sensitivity to CQ, QN or MQ. Although statistical significance was not achieved, a trend toward higher *pfmdr1* expression levels in MQ sensitive isolates was observed ($p = 0.094$).

Interestingly, expression of *pfcr* mRNA could not be detected in two isolates (BC1 and J1) despite confirmation of EF-1a gene expression performed on several occasions. This was not due to any primer mismatch and did not appear to relate to experimental difficulties, although all possibilities cannot be ruled out. This observation needs to be carefully followed up as it has been shown that a *pfcr* knockout is fatal for the parasite [10].

Table 2 Sequence polymorphism in *pfcr*

Isolate/clone	CQ IC ₅₀ (nM)	Amino acid in <i>pfcr</i> gene											
		72	73	74	75	76	198	220	271	326	356	371	
3D7	8	C	V	M	N	K	E	A	Q	N	I	R	
Dd2	48	C	V	I	E	T	E	S	E	S	T	I	
BC1	76	C	V	I	E	T	E	S	E	S	T	I	
BC7	54	C	V	I	E	T	E	S	E	S	T	I	
BC12	49	C	V	I	E	T	E	S	E	S	T	I	
BC22	42	C	V	I	E	T	K*	S	E	S	T	I	
BC31	31	C	V	I	E	T	K*	S	E	S	T	I	
BC35	57	C	V	I	E	T	K*	S	E	S	T	I	
J1	107	C	V	I	E	T	E	S	E	S	T	I	
J3	119	C	V	I	E	T	E	S	E	S	T	I	
J4	114	C	V	I	E	T	E	S	E	S	T	I	
J5	121	C	V	I	E	T	E	S	E	S	T	I	
J6	167	C	V	I	E	T	E	S	E	S	T	I	
J9	123	C	V	I	E	A**	E	S	E	S	T	I	
KS14	67	C	V	I	E	T	E	S	E	S	T	I	
KS21	68	C	V	I	E	T	E	S	E	S	T	I	
KS28	74	C	V	I	E	T	E	S	E	S	T	I	
KS33	55	C	V	I	E	T	E	S	E	S	T	I	
KS50	78	C	V	I	E	T	K*	S	E	S	T	I	
PCM2	75	C	V	I	E	T	E	S	E	S	T	I	
PCM7	51	C	V	I	E	T	E	S	E	S	T	I	
RN54	47	C	V	I	E	T	E	S	E	S	T	I	

* Glutamic acid = > Lysine.

** Lysine == > Alanine.




Figure 2 Correlation analysis between *in vitro* responses (logIC₅₀) and relative *pfcr1* expression in *falciparum* samples. The analysis was deduced using the comparative $\Delta\Delta C_t$ method (log 2^{- $\Delta\Delta C_t$}) using either EF1-alpha as endogenous control gene.




Figure 3 Correlation analysis between *in vitro* responses (logIC₅₀) and relative *Pfmdr1* expression in *falciparum* samples. The analysis was deduced using the comparative $\Delta\Delta C_t$ method (log 2^{- $\Delta\Delta C_t$}) using either EF1-alpha as endogenous control gene.

***Pfmdr1* copy number**

The *pfmdr1* copy number was determined by SYBR Green I real-time PCR. The average copy number of Dd2 was 4.4, which was similar to that previously reported [19]. The *pfmdr1* gene copy number was neither correlated to mRNA expression nor *in vitro* drug susceptibility.

Discussion

Thailand and its borders have historically been linked with the early emergence of drug resistant parasites. The first report of CQ resistance came from this region in the late 1950's. MQ resistance was reported shortly after its deployment, a situation which was worsened despite doubling the drug dosage for treatment. More recently, the Malaria Control Programme of Thailand has introduced artesunate, an artemisinin derivative, deployed in combination with mefloquine to control these multidrug resistant parasites. With respect to CQ susceptibility, molecular studies have confirmed the role for mutation in the *pfcr1* gene and CQR with a possible modulatory influence coming from the *pfmdr1* gene. In contrast, MQ susceptibility has been linked to mutation [6,23,24] and gene copy number of *pfmdr1* [25]. Despite these linkage data, a wide range of observations cannot be fully explained by the currently available genetic evidence. In this study, this issue was investigated in more detail using isolates recently collected from distinct regions of Thailand.

It is unquestionable that genetic polymorphisms of parasite transporter genes have affected the susceptibility to various drugs. In early studies of multidrug resistance in South East Asia, single nucleotide polymorphisms (SNPs) in *pfmdr1* gene such as N86Y have been identified [26]. In Africa, where the 4-aminoquinoline is the main drug for malaria treatment, the frequency of N86Y polymorphism is high (>50%) [12,16,27-29]. However the frequency of N86Y mutation observed in the present study was relatively low, which is in agreement with its frequency in other South East Asian isolates [3,27,30-33]. This might be due to the influence of MQ pressure since mid 1980s after CQ was dismissed in this region [25,34].

Whilst the association of *pfmdr1* polymorphisms and drug sensitivity is still a matter of debate, the level of expression of *pfmdr1* seems to offer a better explanation of anti-malarial drug sensitivity profiles, especially for MQ, QN and artemisinin derivatives. Previous studies have shown the relationship between the increase of *pfmdr1* gene copy number and multidrug resistance phenotypes including artesunate [35-39]. In one study, over-expression of *pfmdr1* was found to be correlated with MQ resistance [40]. On the basis that an increase of gene copy number or gene over-expression may be expected to result in a rise in the mRNA, the levels of

pfmdr1 mRNA and copy number were compared. It is very surprising; the level of mRNA was not correlated to gene copy number. Results failed to reveal an association between *pfmdr1* expression or gene copy number and drug sensitivity. This is analogous to the reported absence of association between Pgh1 protein expression and CQ sensitivity [41]. The authors note that two isolates (BC1 and J1), which lack *pfcr1* expression have different *pfmdr1* expression. For the J1 isolate, of which *pfmdr1* expression was approximately 70-fold over BC1, showed reduced sensitivity to both CQ and MQ. Although the trend of correlation between *pfmdr1* expression and sensitivity to MQ was observed, due to small number of sample size, a statistically significant correlation could not be achieved. These data suggest that increase of copy number and over-expression of *pfmdr1* gene may not necessarily confer drug resistance on its own. Nevertheless, the expression and polymorphism of *pfmdr1* may make a major contribution to drug resistance when present in conjunction with the mutation of other genes [6].

Several studies have described gene mutations in association with CQ-resistance but the exact mechanism of resistance remains unclear. The K76T mutation of *pfcr1* is reported to be highly associated with CQ-resistance. The frequency of this mutation is almost 100% in Thailand. Consequently there seems to be no link between the frequency of this gene mutation and CQ sensitivity. Parasites carrying the K76T mutation with comparable patterns of other *pfcr1* gene mutations still showed a variable degree of CQ-resistance. In fact, the *pfcr1* polymorphisms were similar in all Thai isolates but drug sensitivity profiles were completely different. Data reported from other South East Asian countries, *i.e.*, Philippines, showed different mutations carrying K76T and N326D without 220S residue, together with the novel mutations A144T and L160Y [42]. Furthermore, four novel mutations A144F, L148I, I194T and T333S were observed from Cambodian isolates [11]. These mutation patterns were not observed in Thailand. This suggests that CQ-resistance emerged simultaneously but independently in these neighboring endemic regions.

Pfcr1 polymorphism pattern CVIET was found in all isolates. This pattern is unique to *P. falciparum* isolates from South East Asia. The CVIET pattern, which is different from SVMNT pattern of South America, is more responsive to the calcium channel-blocker verapamil. The chemosensitization phenomenon of verapamil was observed for all isolates even the isolates with lower sensitivity to CQ. Therefore, the CVIET polymorphism pattern seems to confer chemosensitization by verapamil and related compounds.

Full *pfcr1* sequencing revealed the novel 76 haplotype K76A in one isolate. Previously, the substitution of

other amino acids at this codon, *i.e.*, K76I and/or K76N has been reported only in laboratory strains [7,43]. This allelic type replaces lysine (positively charged amino acid) with alanine (non-charged amino acid), similar to the charge loss found with K76T, K76I and K76N mutations. These data augment the growing body of evidence that substitution of non-charged amino acid appears to result in resistance of the parasite to CQ. In addition, the new mutation at position E198K was detected in 4 out of 20 isolates with high CQ sensitivity (low IC₅₀). Based on amino acid sequence, it is speculated that E198K might be located in the fifth of ten PfCRT transmembrane regions, with substitution of glutamic acid (negative charge) to lysine (positive charge). The additional mutation in this position may be critical to the loss of resistance of these parasites to CQ. These findings may support the proposed hypothesis that CQR results from a “charged drug leak”, in which the loss of positive charge in the channel of PfCRT might allow the protonated species of CQ to leak out of the digestive vacuole, thus reducing vacuolar CQ concentration and ultimately conferring resistance [44].

Results obtained from transfection studies showed significant correlation between the extent of protein expression and drug sensitivity profile (increased resistance with increased expression) [10]. In contrast, recent observation of *pfprt* expression and parasites from field isolates showed no correlation between level of mRNA expression and CQ sensitivity [11]. In our study, such absence of correlation between level of mRNA expression and CQ sensitivity was also observed. Furthermore, it was found that no mRNA expression was observed in two isolates. This finding was in contrast with the previous report showing that the knockout of *pfprt* gene would lead the parasite to death. The undetectable level of mRNA expression could be explained by the low or totally absence of *pfprt* expression, or the fact that gene expression may not entirely represent protein expression due to post-transcription process.

Acknowledgements

This work was supported by The Commission on Higher Education, Ministry of Education of Thailand, the National Research University Project of Thailand (NRU), Office of Higher Education Commission and Thailand Research Fund for the scholarship of The Royal Golden Jubilee (RGJ) Ph.D. Program to W.C. K.N. and M.M. were supported by Thailand-Tropical Disease Research Programme (T2), ID 02-2-MAL-24-047. PGB is supported by the MRC and the BBSRC.

Author details

¹Faculty of Allied Health Sciences, Thammasat University, Rangsit, Patumthani 12120, Thailand. ²Division of Molecular and Biochemical Parasitology of Liverpool, University of Liverpool, Pembroke Place, Liverpool L35QA, UK. ³Department of Parasitology, Phramongkutklao College of Medicine, Ratchathewi, Bangkok 10400, Thailand. ⁴Department of Pharmacology and Therapeutics, University of Liverpool, Pembroke Place, Liverpool L35QA, UK.

Authors' contributions

WC performed the molecular genetic studies, participated in the sequence alignment, interpretation of data, performed the statistical analysis and drafted the manuscript. SA participated in the design of the study and data analysis. MM participated in sample collection and *in vitro* sensitivity test. DJ, AO and PB participated in the molecular genetic studies and sequence alignment. KN participated in the design of the study and finalized the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 26 October 2010 Accepted: 15 February 2011

Published: 15 February 2011

References

1. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR: **Epidemiology of drug-resistant malaria.** *Lancet Infect Dis* 2002, **2**:209-218.
2. Bray PG, Howells RE, Ward SA: **Vacuolar acidification and chloroquine sensitivity in *Plasmodium falciparum*.** *Biochem Pharmacol* 1992, **43**:1219-1227.
3. Chaiyaroj SC, Buranakiti A, Angkasekwinai P, Looesuwan S, Cowman AF: **Analysis of mefloquine resistance and amplification of *pfmdr1* in multidrug-resistant *Plasmodium falciparum* isolates from Thailand.** *Am J Trop Med Hyg* 1999, **61**:780-783.
4. Krogstad DJ, Schlesinger PH: **The basis of antimalarial action: non-weak base effects of chloroquine on acid vesicle pH.** *Am J Trop Med Hyg* 1987, **36**:213-220.
5. Verdier F, Le Bras J, Clavier F, Hatin I, Blayo M: **Chloroquine uptake by *Plasmodium falciparum*-infected human erythrocytes during *in vitro* culture and its relationship to chloroquine resistance.** *Antimicrob Agents Chemother* 1985, **27**:561-564.
6. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF: **Pgh1 modulates sensitivity and resistance to multiple antimalarials in *Plasmodium falciparum*.** *Nature* 2000, **403**:906-909.
7. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu AB, Naude B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Welles TE: **Mutations in the *P. falciparum* digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance.** *Mol Cell* 2000, **6**:861-871.
8. Howard EM, Zhang H, Roepe PD: **A novel transporter, PfCRT, confers antimalarial drug resistance.** *J Membr Biol* 2002, **190**:1-8.
9. Sidhu AB, Verdier-Pinard D, Fidock DA: **Chloroquine resistance in *Plasmodium falciparum* malaria parasites conferred by *pfprt* mutations.** *Science* 2002, **298**:210-213.
10. Waller KL, Muhle RA, Ursos LM, Horrocks P, Verdier-Pinard D, Sidhu AB, Fujioka H, Roepe PD, Fidock DA: **Chloroquine resistance modulated *in vitro* by expression levels of the *Plasmodium falciparum* chloroquine resistance transporter (PfCRT).** *J Biol Chem* 2003, **278**:33593-33601.
11. Durrand V, Berry A, Sem R, Glaziou P, Beaudou J, Fandeur T: **Variations in the sequence and expression of the *Plasmodium falciparum* chloroquine resistance transporter (PfCRT) and their relationship to chloroquine resistance *in vitro*.** *Mol Biochem Parasitol* 2004, **136**:273-285.
12. Rowe AW, Eyster E, Kellner A: **Liquid nitrogen preservation of red blood cells for transfusion; a low glycerol-rapid freeze procedure.** *Cryobiology* 1968, **5**:119-128.
13. Trager W, Jensen JB: **Human malaria parasites in continuous culture.** *Science* 1976, **193**:673-675.
14. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD: **Quantitative assessment of antimalarial activity *in vitro* by a semiautomated microdilution technique.** *Antimicrob Agents Chemother* 1979, **16**:710-718.
15. Wooden J, Gould EE, Paull AT, Sibley CH: ***Plasmodium falciparum*: a simple polymerase chain reaction method for differentiating strains.** *Exp Parasitol* 1992, **75**:207-212.
16. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, Welles TE, Plowe CV, Coulbaly D: **A molecular marker for chloroquine-resistant *falciparum* malaria.** *N Engl J Med* 2001, **344**:257-263.
17. Chomczynski P: **A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples.** *Biotechniques* 1993, **15**:532-534.

18. Owen A, Chandler B, Bray PG, Ward SA, Hart CA, Back DJ, Khoo SH: Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. *J Virol* 2004, **78**:12022-12029.
19. Ferreira ID, Rosario VE, Cravo PV: Real-time quantitative PCR with SYBR Green I detection for estimating copy numbers of nine drug resistance candidate genes in *Plasmodium falciparum*. *Malar J* 2006, **5**:1.
20. Vijaykudga S, Rojanawatsirivej C, Cholpol S, Phoungmanee D, Nakavej A, Wongsrichanalai C: *In vivo* sensitivity monitoring of mefloquine monotherapy and artesunate-mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. *Trop Med Int Health* 2006, **11**:211-219.
21. Cerutti C Jr, Marques AC, de Alencar FEC, Durlacher RR, Alween A, Segurado AAC, Pang L, Zalis MG: Antimalarial drug susceptibility testing of *Plasmodium falciparum* in Brazil using a radioisotope method. *Mem Inst Oswaldo Cruz* 1999, **94**:803-809.
22. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaijun L, Patel R, Laing K, Looareesuwan S, White NJ, Nosten F, Krishna S: Mefloquine resistance in *Plasmodium falciparum* and increased pfmdr1 gene copy number. *Lancet* 2004, **364**:438-447.
23. Basco LK, Ringwald P: Molecular epidemiology of malaria in Cameroon. X. Evaluation of PFMDR1 mutations as genetic markers for resistance to amino alcohols and artemisinin derivatives. *Am J Trop Med Hyg* 2002, **66**:667-671.
24. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC: The tyrosine-86 allele of the pfmdr1 gene of *Plasmodium falciparum* is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. *Mol Biochem Parasitol* 2000, **108**:13-23.
25. Price RN, Cassar C, Brockman A, Duraisingh M, Van Vugt M, White NJ, Nosten F, Krishna S: The pfmdr1 gene is associated with a multidrug-resistant phenotype in *Plasmodium falciparum* from the western border of Thailand. *Antimicrob Agents Chemother* 1999, **43**:2943-2949.
26. Foote SJ, Kyle DE, Martin RK, Oduola AM, Forsyth K, Kemp DJ, Cowman AF: Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in *Plasmodium falciparum*. *Nature* 1990, **345**:255-258.
27. Adagu IS, Warhurst DC: *Plasmodium falciparum*: linkage disequilibrium between loci in chromosomes 7 and 5 and chloroquine selective pressure in Northern Nigeria. *Parasitology* 2001, **123**:219-224.
28. Randrianavelojosia M, Raheinjafy RH, Mercereau-Puijalon O, Ariey F, Bedja SA: *Plasmodium falciparum* resistant to chloroquine and to pyrimethamine in Comoros. *Parasite* 2004, **11**:419-423.
29. Thomas SM, Ndir O, Dieng T, Mboup S, Wypij D, Maguire JH, Wirth DF: *In vitro* chloroquine susceptibility and PCR analysis of pfcr1 and pfmdr1 polymorphisms in *Plasmodium falciparum* isolates from Senegal. *Am J Trop Med Hyg* 2002, **66**:474-480.
30. Huaman MC, Yoshinaga K, Suryanatha A, Suarsana N, Kanbara H: Short report: polymorphisms in the chloroquine resistance transporter gene in *Plasmodium falciparum* isolates from Lombok, Indonesia. *Am J Trop Med Hyg* 2004, **71**:40-42.
31. Labbe AC, Bualombai P, Pillai DR, Zhong KJ, Vanisaveth V, Hongvanthong B, Looareesuwan S, Kain KC: Molecular markers for chloroquine-resistant *Plasmodium falciparum* malaria in Thailand and Laos. *Ann Trop Med Parasitol* 2001, **95**:781-788.
32. Lim P, Chy S, Ariey F, Incardona S, Chim P, Sem R, Denis MB, Hewitt S, Hoyer S, Socheat D, Mercereau-Puijalon O, Fandeur T: Pfcr1 polymorphism and chloroquine resistance in *Plasmodium falciparum* strains isolated in Cambodia. *Antimicrob Agents Chemother* 2003, **47**:87-94.
33. Vathsala PG, Pramanik A, Dhanasekaran S, Devi CU, Pillai CR, Subbarao SK, Ghosh SK, Tiwari SN, Sathyannarayan TS, Deshpande PR, Mishra GC, Dash AP, Ranqarajan PN, Padmanaban G: Widespread occurrence of the *Plasmodium falciparum* chloroquine resistance transporter (Pfcr1) gene haplotype SVMNT in *P. falciparum* malaria in India. *Am J Trop Med Hyg* 2004, **70**:256-259.
34. Sisowath C, Ferreira PE, Bustamante LY, Dahlstrom S, Martensson A, Bjorkman A, Krishna S, Gil JP: The role of pfmdr1 in *Plasmodium falciparum* tolerance to artemether-lumefantrine in Africa. *Trop Med Int Health* 2007, **12**:736-742.
35. Basco LK, de Pecoulas PE, Le Bras J, Wilson CM: *Plasmodium falciparum*: molecular characterization of multidrug-resistant Cambodian isolates. *Exp Parasitol* 1996, **82**:97-103.
36. Basco LK, Le Bras J, Rhoades Z, Wilson CM: Analysis of pfmdr1 and drug susceptibility in fresh isolates of *Plasmodium falciparum* from subsaharan Africa. *Mol Biochem Parasitol* 1995, **74**:157-166.
37. Zalis MG, Pang L, Silveira MS, Milhous WK, Wirth DF: Characterization of *Plasmodium falciparum* isolated from the Amazon region of Brazil: evidence for quinine resistance. *Am J Trop Med Hyg* 1998, **58**:630-637.
38. Rogers WO, Sem R, Tero T, Chim P, Lim P, Muth S, Socheat D, Ariey F, Wongsrichanalai C: Failure of artesunate-mefloquine combination therapy for uncomplicated *Plasmodium falciparum* malaria in southern Cambodia. *Malar J* 2009, **8**:10.
39. Lim P, Alker AP, Khim N, Shah NK, Incardona S, Doung S, Yi P, Bouth DM, Bouchier C, Puijalon OM, Meshnick SR, Wongsrichanalai C, Fandeur T, Le Bras J, Ringwald P, Ariey F: Pfmdr1 copy number and artemisinin derivatives combination therapy failure in falciparum malaria in Cambodia. *Malar J* 2009, **8**:11-18.
40. Wilson CM, Volkman SK, Thaithong S, Martin RK, Kyle DE, Milhous WK, Wirth DF: Amplification of pfmdr1 associated with mefloquine and halofantrine resistance in *Plasmodium falciparum* from Thailand. *Mol Biochem Parasitol* 1993, **57**:151-160.
41. Cowman AF, Karcz SR, Glalatis D, Culvenor JG: A P-glycoprotein homologue of *Plasmodium falciparum* is localized on the digestive vacuole. *J Cell Biol* 1991, **113**:1033-1042.
42. Chen N, Kyle DE, Pasay C, Fowler EV, Baker J, Peters JM, Cheng Q: pfcr1 Allelic types with two novel amino acid mutations in chloroquine-resistant *Plasmodium falciparum* isolates from the Philippines. *Antimicrob Agents Chemother* 2003, **47**:3500-3505.
43. Cooper RA, Ferdig MT, Su XZ, Ursos LM, Mu J, Nomura T, Fujioka H, Fidock DA, Roepe PD, Wellem TE: Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in *Plasmodium falciparum*. *Mol Pharmacol* 2002, **61**:35-42.
44. Johnson DJ, Fidock DA, Mungthin M, Lakshmanan V, Sidhu AB, Bray PG, Ward SA: Evidence for a central role for PfCRT in conferring *Plasmodium falciparum* resistance to diverse antimalarial agents. *Mol Cell* 2004, **15**:867-877.

doi:10.1186/1475-2875-10-42

Cite this article as: Chaijaroenkul et al.: Sequence and gene expression of chloroquine resistance transporter (pfcr1) in the association of *in vitro* drugs resistance of *Plasmodium falciparum*. *Malaria Journal* 2011 **10**:42.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

